137 related articles for article (PubMed ID: 25714918)
1. A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma.
Raber S; Mandema JW; Li H; Nickens DJ
J Ocul Pharmacol Ther; 2015 May; 31(4):189-97. PubMed ID: 25714918
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
4. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
Aptel F; Cucherat M; Denis P
J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
[TBL] [Abstract][Full Text] [Related]
8. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
van der Valk R; Webers CA; Schouten JS; Zeegers MP; Hendrikse F; Prins MH
Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
[TBL] [Abstract][Full Text] [Related]
9. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.
Orme M; Collins S; Dakin H; Kelly S; Loftus J
Curr Med Res Opin; 2010 Mar; 26(3):511-28. PubMed ID: 20014995
[TBL] [Abstract][Full Text] [Related]
10. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
12. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
13. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
14. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
15. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
16. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
17. Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy.
Paranhos A; Mendonça M; Silva MJ; Giampani J; Torres RJ; Della Paolera M; Russ H; Lottenberg CL
J Ocul Pharmacol Ther; 2010 Dec; 26(6):611-5. PubMed ID: 21029020
[TBL] [Abstract][Full Text] [Related]
18. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
Nixon DR
J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination.
Centofanti M; Oddone F; Gandolfi S; Hommer A; Boehm A; Tanga L; Sangermani C; Sportelli V; Haustein M; Manni G; Rossetti L
Am J Ophthalmol; 2010 Oct; 150(4):575-80. PubMed ID: 20688314
[TBL] [Abstract][Full Text] [Related]
20. Travoprost--a new prostaglandin analogue for the treatment of glaucoma.
Whitson JT
Expert Opin Pharmacother; 2002 Jul; 3(7):965-77. PubMed ID: 12083996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
